Goldman Sachs Resumes Coverage of Illumina | GenomeWeb

Goldman Sachs Resumes Coverage of Illumina

May 03, 2012

|

NEW YORK (GenomeWeb News) – Investment bank Goldman Sachs has reinstated coverage of Illumina, giving it a Neutral rating and a 12-month price target on its stock of $48.

The bank suspended coverage of Illumina shortly after Roche launched its hostile bid for the San Diego firm. Goldman Sachs was an advisor to Illumina on the proposed deal, which ended when Roche abandoned its pursuit last month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Spiders and Scorpions, Oh My!

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

Keep It Secret

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Page Joins Chronic Disease Startup

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

This Week in Cell

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.